Trial reportHaematologica2018
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.Blood advances · 2025Trial
- A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.Transplantation and cellular therapy · 2023Trial
- Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.Bone marrow transplantation · 2026Article
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Journal of hematology & oncology · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Transplantation and cellular therapy · 2022Article
- Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors.Bone marrow transplantation · 2021Article
- Translational Clinical Strategies for the Prevention of Gastrointestinal Tract GraftFrontiers in immunology · 2021Review
- Current Status and Future Directions in Graft-Clinical hematology international · 2020Review
- Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.Bone marrow transplantation · 2020Article
- Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.Frontiers in immunology · 2020Review
- Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease.Frontiers in immunology · 2020Review
- How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Frontiers in immunology · 2020Review
- Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.International journal of hematology · 2019Article
- On the role of the immunoproteasome in transplant rejection.Immunogenetics · 2019Review
- Bortezomib for prevention of acute graft-Haematologica · 2018Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 5 institutions in 1 country.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA john_koreth@dfci.harvard.edu.
Haesook T KimDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA.
Paulina B LangeDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Samuel J PoryandaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Carol G ReynoldsDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Sharmila Chamling RaiDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Corey S CutlerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Brett GlotzbeckerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Rushdia YusufDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Sarah NikiforowDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Yi-Bin ChenMassachusetts General Hospital Cancer Center, Boston, MA.
Bimalangshu DeyMassachusetts General Hospital Cancer Center, Boston, MA.
Malgorzata McMastersBeth Israel Deaconess Hospital Cancer Center, Boston, MA.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Bruce R BlazarUniversity of Minnesota Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN, USA.
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Dana-Farber Cancer Institute · USHarvard University · USMassachusetts General Hospital · USBeth Israel Deaconess Hospital · USUniversity of Minnesota · US
Funding
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MManipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7MReconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5MNCI NIH HHS P01 CA142106NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560NHLBI NIH HHS R01 HL118979
Abstract
Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-
Indexed as
AdultAgedAllograftsAntineoplastic Combined Chemotherapy ProtocolsBortezomibFemaleGraft vs Host DiseaseHematologic DiseasesHematopoietic Stem Cell TransplantationHumansImmunosuppression TherapyMaleMethotrexateMiddle AgedSurvival AnalysisTacrolimusBortezomibMethotrexateTacrolimus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.